| Recruiting | A Study of Abemaciclib and Radiation Therapy in People With Metastatic Breast Cancer NCT06678269 | Memorial Sloan Kettering Cancer Center | Phase 1 |
| Withdrawn | Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs NCT04985357 | Travera Inc | — |
| Recruiting | The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer NCT06439693 | Dana-Farber Cancer Institute | Phase 2 |
| Recruiting | Discontinuation of Maintenance HER-2 Directed Therapy in Long-Term Survivors of Metastatic HER-2 Positive Brea NCT05959291 | University of Miami | N/A |
| Active Not Recruiting | Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positi NCT05840211 | Gilead Sciences | Phase 3 |
| Completed | Ask Questions (ASQ):Implementation of a Communication Intervention NCT05025748 | Barbara Ann Karmanos Cancer Institute | N/A |
| Unknown | Image-guided Targeted Doxorubicin Delivery With Hyperthermia to Optimize Loco-regional Control in Breast Cance NCT03749850 | UMC Utrecht | Phase 1 |
| Unknown | Improving Patient and Caregiver Understanding of Risks and Benefits of Immunotherapy for Advanced Cancer NCT04670445 | Massachusetts General Hospital | N/A |
| Unknown | Breast Stereotactic Radiotherapy to Primary Tumors in Metastatic Patients NCT05229575 | Campus Bio-Medico University | N/A |
| Withdrawn | Compare the Efficacy of Surgery Combined With Systemic Therapy and Pure Systemic Therapy in Breast Cancer Pati NCT04199520 | Henan Cancer Hospital | Phase 2 |
| Unknown | Canady Helios Cold Plasma Scalpel Treatment at the Surgical Margin and Macroscopic Tumor Sites NCT04267575 | Jerome Canady, M.D. | N/A |
| Active Not Recruiting | Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectabl NCT03971409 | Laura Huppert, MD, BA | Phase 2 |
| Recruiting | Clinical Study of Personalized Chemotherapy for Breast Cancer With Low Doses of Cyclophosphamide NCT06361264 | KARANAHAN | EARLY_Phase 1 |
| Unknown | Dibenzyl Trisulphide (GUINEAHEN WEED) for Stage IV Cancer NCT04113096 | The University of The West Indies | EARLY_Phase 1 |
| Terminated | Atezolizumab and Cobimetinib or Idasanutlin in Participants With Stage IV or Unresectable Recurrent Estrogen R NCT03566485 | Vanderbilt-Ingram Cancer Center | Phase 1 / Phase 2 |
| Completed | G1T48, an Oral SERD, Alone and in Combination With Palbociclib in ER-Positive, HER2-Negative Advanced Breast C NCT03455270 | G1 Therapeutics, Inc. | Phase 1 |
| Completed | Mindfulness-Based Stress Reduction in Helping Participants With Metastatic Breast Cancer NCT03683147 | Roswell Park Cancer Institute | N/A |
| Completed | Acceptance and Commitment Therapy in Improving Well-Being in Patients With Stage III-IV Cancer and Their Partn NCT03112668 | Rutgers, The State University of New Jersey | N/A |
| Completed | 4-1BB Agonist Monoclonal Antibody PF-05082566 With Trastuzumab Emtansine or Trastuzumab in Treating Patients W NCT03364348 | George W. Sledge Jr. | Phase 1 |
| Terminated | Denosumab in Treating Patients With ER and/or PR Positive, HER2 Negative Metastatic Breast Cancer With Bone Me NCT03070002 | Northwestern University | Phase 2 |
| Terminated | Ipilimumab and Nivolumab in Treating Patients With Recurrent Stage IV HER2 Negative Inflammatory Breast Cancer NCT02892734 | Northwestern University | Phase 2 |
| Recruiting | Pembrolizumab and Carboplatin in Treating Patients With Circulating Tumor Cells Positive Metastatic Breast Can NCT03213041 | Northwestern University | Phase 2 |
| Completed | Carboplatin With or Without Atezolizumab in Treating Patients With Stage IV Triple Negative Breast Cancer NCT03206203 | Vanderbilt-Ingram Cancer Center | Phase 2 |
| Completed | Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer NCT03154190 | Stanford University | N/A |
| Terminated | Copanlisib, Letrozole, and Palbociclib in Treating Patients With Hormone Receptor Positive HER2 Negative Stage NCT03128619 | Jonsson Comprehensive Cancer Center | Phase 1 |
| Completed | Alisertib With or Without Fulvestrant in Treating Patients With Locally Advanced or Metastatic, Endocrine-Resi NCT02860000 | Mayo Clinic | Phase 2 |
| Unknown | Pembrolizumab and Capecitabine in Treating Patients With Locally Advanced or Metastatic Triple Negative or Hor NCT03044730 | Northwestern University | Phase 2 |
| Completed | Ultrasound in Detecting Taxane-Induced Neuropathy in Patients With Breast Cancer NCT03139435 | Wake Forest University Health Sciences | N/A |
| Completed | Prospective Cohort Study Depending on the Use of Palliative Care for Advanced Stage of Cancer Patients NCT03222258 | Seoul National University Hospital | — |
| Completed | Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors NCT02897375 | Emory University | Phase 1 |
| Completed | S1415CD, Trial Assessing CSF Prescribing Effectiveness and Risk (TrACER) NCT02728596 | SWOG Cancer Research Network | N/A |
| Terminated | Palbociclib in Treating Patients With Metastatic HER-2 Positive Breast Cancer With Brain Metastasis NCT02774681 | Northwestern University | Phase 2 |
| Terminated | Rebastinib Plus Antitubulin Therapy With Paclitaxel or Eribulin in Metastatic Breast Cancer NCT02824575 | Montefiore Medical Center | Phase 1 |
| Completed | Vaccine Therapy in Treating Patients With Stage IV HLA-A2 and HER2 Positive Breast or Ovarian Cancer Receiving NCT00194714 | University of Washington | Phase 1 / Phase 2 |
| Completed | Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer NCT02657889 | Tesaro, Inc. | Phase 1 / Phase 2 |
| Completed | Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative NCT02648477 | City of Hope Medical Center | Phase 2 |
| Completed | Galunisertib and Paclitaxel in Treating Patients With Metastatic Androgen Receptor Negative (AR-) Triple Negat NCT02672475 | Vanderbilt-Ingram Cancer Center | Phase 1 |
| Terminated | TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Pro NCT02650635 | Mayo Clinic | Phase 1 |
| Completed | MEDI4736 and Tremelimumab in Treating Patients With Metastatic HER2 Negative Breast Cancer NCT02536794 | Northwestern University | Phase 2 |
| Completed | Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR Mutations NCT02646319 | Mayo Clinic | EARLY_Phase 1 |
| Completed | 18F-FSPG PET/CT for Cancer Patients on Therapy NCT02599194 | Andrei Iagaru | Phase 2 |
| Terminated | Taselisib and Enzalutamide in Treating Patients With Androgen Receptor Positive Triple-Negative Metastatic Bre NCT02457910 | Vanderbilt-Ingram Cancer Center | Phase 1 / Phase 2 |
| Active Not Recruiting | Vaccine Therapy in Treating Patients With HER2-Negative Stage III-IV Breast Cancer NCT02157051 | University of Washington | Phase 1 |
| Completed | Oxaliplatin in Treating Patients With Metastatic Breast Cancer NCT02077998 | University of California, Davis | EARLY_Phase 1 |
| Withdrawn | Role of Hyaluronic Acid in Causing Cancer Stem Cell Growth in the Bones of Patients With Breast Cancer NCT02331212 | Wake Forest University Health Sciences | — |
| Active Not Recruiting | Copper Cu 64-DOTA-Trastuzumab PET in Predicting Response to Treatment With Ado-Trastuzumab Emtansine in Patien NCT02226276 | City of Hope Medical Center | N/A |
| Completed | Alisertib and Fulvestrant in Treating Patients With Hormone Receptor Positive Breast Cancer That is Metastatic NCT02219789 | Mayo Clinic | Phase 1 |
| Terminated | Phase II Study of Everolimus Beyond Progression NCT02269670 | Emory University | Phase 2 |
| Terminated | Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kid NCT02273752 | Emory University | Phase 2 |
| Completed | Mucoadhesive Oral Wound Rinse in Preventing and Treating Stomatitis in Patients With ER- or PR-Positive Metast NCT02015559 | Jonsson Comprehensive Cancer Center | Phase 2 |
| Completed | Eribulin Mesylate and Everolimus in Treating Patients With Triple-Negative Metastatic Breast Cancer NCT02120469 | City of Hope Medical Center | Phase 1 |
| Completed | Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Breast Cancer, Non-small Cell Lung Ca NCT02206334 | NRG Oncology | Phase 1 |
| Withdrawn | Dynamic Contrast Enhanced MRI in Patients With Advanced Breast or Pancreatic Cancer With Metastases to the Liv NCT01741597 | City of Hope Medical Center | Phase 1 |
| Completed | BP-C1 in Short-term Treatment of Thai Patients With Metastatic Breast Cancer NCT03603197 | Meabco A/S | Phase 2 |
| Completed | Trastuzumab Emtansine in Treating Patients With HER2-Positive Metastatic or Locally Advanced Breast Cancer Tha NCT01816035 | University of Washington | Phase 1 |
| Completed | BYL719 + T-DM1 in HER2(+) Metastatic Breast Cancer Pts Who Progress on Prior Trastuzumab & Taxane Tx NCT02038010 | Northwestern University | Phase 1 |
| Completed | Ganetespib, Paclitaxel, Trastuzumab and Pertuzumab for Metastatic Human Epidermal Growth Factor Receptor 2 Pos NCT02060253 | Memorial Sloan Kettering Cancer Center | Phase 1 |
| Terminated | Romidepsin and Abraxane in Treating Patients With Metastatic Inflammatory Breast Cancer NCT01938833 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Phase 1 / Phase 2 |
| Completed | Vaccine Therapy With or Without Polysaccharide-K in Patients With Stage IV HER2 Positive Breast Cancer Receivi NCT01922921 | University of Washington | Phase 1 / Phase 2 |
| Completed | Propranolol Hydrochloride in Treating Patients With Locally Recurrent or Metastatic Solid Tumors That Cannot B NCT02013492 | William Carson | EARLY_Phase 1 |
| Completed | BP-C1 in Metastatic Breast Cancer Patients NCT01861509 | Meabco A/S | Phase 1 |
| Completed | Eribulin Mesylate in Treating Patients With Previously Treated Metastatic Breast Cancer NCT01908101 | University of Washington | Phase 2 |
| Withdrawn | Investigational Drug in Combination With Two Chemotherapy Drugs in Women With Locally Recurrent or Metastatic NCT01349088 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Phase 1 / Phase 2 |
| Completed | Health Education Intervention in Reducing Weight Gain in Patients With Newly Diagnosed Stage I-IV Breast Cance NCT01941784 | Wake Forest University Health Sciences | N/A |
| Terminated | PET/CT in Evaluating Response to Chemotherapy in Patients With Breast Cancer NCT01712815 | University of Southern California | N/A |
| Terminated | Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV Infection NCT01249443 | AIDS Malignancy Consortium | Phase 1 |
| Completed | Carboplatin, Gemcitabine Hydrochloride, and Mifepristone in Treating Patients With Advanced Breast Cancer or R NCT02046421 | University of Chicago | Phase 1 |
| Completed | Diagnostic Accuracy and Safety Study of FES PET/CT in Assessment of ER Status of Recurrent or Metastatic Breas NCT01986569 | Asan Medical Center | Phase 3 |
| Completed | Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Metastatic Triple-Negative Breast Cancer NCT01964924 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabin NCT01881230 | Celgene | Phase 2 / Phase 3 |
| Completed | Comprehensive Gene Sequencing in Guiding Treatment Recommendations Patients With Metastatic or Recurrent Solid NCT01987726 | Ohio State University Comprehensive Cancer Center | — |
| Terminated | GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast NCT01918306 | Vanderbilt-Ingram Cancer Center | Phase 1 / Phase 2 |
| Terminated | Capecitabine, Cyclophosphamide, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With HER2-Positive NCT01873833 | University of Southern California | Phase 2 |
| Active Not Recruiting | Pertuzumab, Trastuzumab, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With NCT01730833 | City of Hope Medical Center | Phase 2 |
| Completed | Phase 1b/2 Trial Using Lapatinib, Everolimus and Capecitabine for Treatment of HER-2 Positive Breast Cancer Wi NCT01783756 | Jonsson Comprehensive Cancer Center | Phase 1 / Phase 2 |
| Terminated | Chemotherapy Before Surgery and Tissue Sample Collection in Patients With Stage IIA-IIIC Breast Cancer NCT01897441 | Albert Einstein College of Medicine | N/A |
| Completed | Viral Therapy In Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck C NCT01846091 | Mayo Clinic | Phase 1 |
| Active Not Recruiting | BYL719 and Letrozole in Post-Menopausal Patients With Hormone Receptor-Positive Metastatic Breast Cancer NCT01791478 | Vanderbilt-Ingram Cancer Center | Phase 1 |
| Completed | 18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis NCT01806675 | Sanjiv Sam Gambhir | Phase 1 / Phase 2 |
| Completed | BP-C1 Monotherapy in Patients With Metastatic Breast Cancer Cancer: Estimation of Optimal Duration of Treatmen NCT03789019 | Meabco A/S | Phase 2 |
| Completed | Cabergoline in Metastatic Breast Cancer NCT01730729 | Northwestern University | EARLY_Phase 1 |
| Completed | BP-C1 in Short-term Treatment of Patients With Metastatic Breast Cancer NCT02783794 | Meabco A/S | Phase 2 |
| Terminated | Vaccine Therapy in Treating Patients With Stage IV Hormone Receptor Positive Breast Cancer NCT01729884 | University of Washington | Phase 2 |
| Withdrawn | A Pilot Study of Irinotecan in Patients With Breast Cancer and CNS Metastases NCT01939483 | University of California, Irvine | N/A |
| Completed | Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Hormone Therapy NCT01720602 | University of Washington | N/A |
| Terminated | Questionnaires in Identifying Upper Extremity Function and Quality of Life After Treatment in Patients With Br NCT02370264 | University of Southern California | N/A |
| Completed | Phase I: At-Home Support for Rural Women Using Group Video Calling NCT01672684 | Stanford University | Phase 1 |
| Terminated | Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Meta NCT01705340 | National Cancer Institute (NCI) | Phase 1 |
| Withdrawn | Ex Vivo-Expanded HER2-Specific T Cells and Cyclophosphamide After Vaccine Therapy in Treating Patients With HE NCT01219907 | University of Washington | Phase 1 |
| Withdrawn | Mechanical Stimulation in Preventing Bone Density Loss in Patients Undergoing Donor Stem Cell Transplant NCT01558778 | Roswell Park Cancer Institute | N/A |
| Completed | Tivantinib in Treating Patients With Recurrent or Metastatic Breast Cancer NCT01575522 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | PTX-200, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide in Treating Patients With Stage IIB-IV Br NCT01697293 | Prescient Therapeutics, Ltd. | Phase 1 / Phase 2 |
| Completed | BKM120 and Fulvestrant for Treating Postmenopausal Patients With Estrogen Receptor-Positive Stage IV Breast Ca NCT01339442 | Washington University School of Medicine | Phase 1 |
| Completed | Nab-paclitaxel (Abraxane) With or Without Mifepristone in Patients With Advanced Breast Cancer NCT01493310 | University of Chicago | Phase 1 |
| Completed | Vaccine Therapy in Combination With Rintatolimod and/or Sargramostim in Treating Patients With Stage II-IV HER NCT01355393 | University of Washington | Phase 1 / Phase 2 |
| Completed | Vaccination of High Risk Breast Cancer Patients NCT01390064 | University of Arkansas | Phase 1 |
| Completed | Early Surgery or Standard Palliative Therapy in Treating Patients With Stage IV Breast Cancer NCT01242800 | Eastern Cooperative Oncology Group | N/A |
| Completed | Liposomal Cytarabine and High-Dose Methotrexate in Treating Patients With Central Nervous System Metastases Fr NCT00992602 | University of Washington | Phase 2 |
| Active Not Recruiting | Positron Emission Tomography in Women With Advanced HER2-Positive Breast Cancer NCT01093612 | City of Hope Medical Center | N/A |
| Completed | Akt Inhibitor MK2206 in Treating Patients With Advanced Breast Cancer NCT01277757 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Abraxane With or Without Tigatuzumab in Patients With Metastatic, Triple Negative Breast Cancer NCT01307891 | University of Alabama at Birmingham | Phase 2 |
| Completed | Pilot Study Estradiol Followed by Exemestane Hormone Receptor + Metastatic Breast Cancer NCT01385280 | University of Arizona | N/A |
| Withdrawn | Stereotactic Image-Guided Navigation During Breast Reconstruction in Patients With Breast Cancer NCT01729832 | Ohio State University Comprehensive Cancer Center | N/A |
| Completed | Tamoxifen Citrate in Treating Patients With Metastatic or Recurrent Breast Cancer NCT01124695 | ECOG-ACRIN Cancer Research Group | Phase 2 |
| Completed | MK2206 and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Metastatic Brea NCT01263145 | National Cancer Institute (NCI) | Phase 1 |
| Withdrawn | Azacitidine in Treating Patients With Triple Negative Stage I-IV Invasive Breast Cancer That Can Be Removed By NCT01292083 | University of Southern California | N/A |
| Completed | Paclitaxel and Bavituximab in Treating Patients With HER2-Negative Metastatic Breast Cancer NCT01288261 | University of Arizona | Phase 1 |
| Terminated | Lapatinib Ditosylate and Akt Inhibitor MK2206 in Treating Women With Metastatic Breast Cancer NCT01281163 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Veliparib in Combination With Carboplatin and Paclitaxel in Treating Patients With Locally Advanced or Metasta NCT01281150 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Weekly Doses of Cilengitide and Paclitaxel in Treating Patients With Advanced Solid Tumors That Cannot Be Remo NCT01276496 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | Cryotherapy in Preventing Peripheral Neuropathy and Nail Toxicity in Patients With Breast Cancer Who Are Recei NCT01243541 | Northwestern University | N/A |
| Completed | Akt Inhibitor MK2206 in Combination With Lapatinib Ditosylate in Patients With Advanced or Metastatic Solid Tu NCT01245205 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Aromatase Inhibitor Therapy NCT01153672 | University of Washington | N/A |
| Terminated | RO4929097 And Exemestane in Treating Pre- and Postmenopausal Patients With Advanced or Metastatic Breast Cance NCT01149356 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors NCT01233505 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | Endoscopic Breast Surgery in Treating Patients With Breast Cancer NCT01222377 | University of Southern California | N/A |
| Completed | Veliparib, Cisplatin, and Vinorelbine Ditartrate in Treating Patients With Recurrent and/or Metastatic Breast NCT01104259 | University of Washington | Phase 1 |
| Terminated | Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload NCT01159067 | City of Hope Medical Center | Phase 2 |
| Completed | Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors NCT01155258 | University of Southern California | Phase 1 |
| Completed | Breast Cancer Rehabilitation Program in Improving Quality of Life in Breast Cancer Survivors NCT01113554 | Wake Forest University Health Sciences | N/A |
| Completed | RO4929097 and Capecitabine in Treating Patients With Refractory Solid Tumors NCT01158274 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | Gamma-secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced, Metastatic, o NCT01151449 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Ixabepilone and Vorinostat in Treating Patients With Metastatic Breast Cancer NCT01084057 | City of Hope Medical Center | Phase 1 |
| Completed | Alkaline Water in Reducing Skin Toxicity in Women With Breast Cancer Undergoing Radiation Therapy NCT01487954 | Case Comprehensive Cancer Center | Phase 2 |
| Completed | Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors NCT01131234 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | Paclitaxel, Carboplatin, and Panitumumab in Treating Patients With Metastatic Breast Cancer NCT01009983 | Wake Forest University Health Sciences | Phase 2 |
| Terminated | Rosuvastatin in Treating Women With Cardiovascular Complications Who Are Undergoing Chemotherapy For Breast Ca NCT01051401 | Wake Forest University Health Sciences | Phase 1 |
| Completed | Vaccine Therapy and 1-MT in Treating Patients With Metastatic Breast Cancer NCT01042535 | H. Lee Moffitt Cancer Center and Research Institute | Phase 1 / Phase 2 |
| Completed | Window of Opportunity Study Targeting the Inflammatory Milieu NCT01881048 | University of Colorado, Denver | EARLY_Phase 1 |
| Terminated | RO4929097 and Vismodegib in Treating Patients With Breast Cancer That is Metastatic or Cannot Be Removed By Su NCT01071564 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | Calcium and Magnesium in Preventing Peripheral Neuropathy Caused by Ixabepilone in Patients With Breast Cancer NCT00998738 | Mayo Clinic | Phase 3 |
| Completed | Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer NCT01037790 | Abramson Cancer Center at Penn Medicine | Phase 2 |
| Terminated | Cediranib Maleate and Whole Brain Radiation Therapy in Patients With Brain Metastases From Non-Small Cell Lung NCT00937482 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Dose-finding Study of BP-C1 in Patients With Stage IV Breast Cancer NCT04298333 | Meabco A/S | Phase 1 |
| Completed | Hypofractionated Image Guided Radiation Therapy in Treating Patients With Stage IV Breast Cancer NCT01706432 | University of Chicago | — |
| Completed | Topical Imiquimod and Abraxane in Treating Patients With Advanced Breast Cancer NCT00821964 | University of Washington | Phase 2 |
| Completed | Vaccine Therapy in Treating Patients With Stage IV Breast Cancer NCT00791037 | University of Washington | Phase 1 / Phase 2 |
| Completed | F-18 16 Alpha-Fluoroestradiol-Labeled Positron Emission Tomography in Predicting Response to First-Line Hormon NCT00602043 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant NCT00795769 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Nab-Paclitaxel and Bevacizumab Followed By Bevacizumab and Erlotinib in Metastatic Breast Cancer NCT00733408 | University of Washington | Phase 2 |
| Terminated | Bevacizumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER-2/NEU NCT00520975 | National Cancer Institute (NCI) | Phase 3 |
| Completed | Saracatinib in Treating Patients With Metastatic or Locally Advanced Breast Cancer That Cannot Be Removed By S NCT00559507 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Medroxyprogesterone +/- Cyclophosphamide & Methotrexate in Hormone Receptor-Negative Recurrent/Metastatic Brea NCT00577122 | Indiana University | Phase 2 |
| Completed | Pazopanib in Treating Patients With Recurrent or Metastatic Breast Cancer NCT00509587 | National Cancer Institute (NCI) | Phase 2 |
| Completed | VEGF Trap in Treating Patients With Metastatic Breast Cancer NCT00369655 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Vorinostat and Trastuzumab in Treating Patients With Metastatic or Locally Recurrent Breast Cancer NCT00258349 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | AFP464 in Treating Patients With Metastatic or Refractory Solid Tumors That Cannot Be Removed By Surgery NCT00348699 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Phase I-II Study of Vorinostat, Paclitaxel, and Bevacizumab in Metastatic Breast Cancer NCT00368875 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem NCT00408681 | Fred Hutchinson Cancer Center | N/A |
| Completed | Doxorubicin Hydrochloride, Cyclophosphamide, and Filgrastim Followed By Paclitaxel Albumin-Stabilized Nanopart NCT00407888 | University of Washington | Phase 2 |
| Completed | Doxorubicin Hydrochloride Liposome, Cyclophosphamide, and Trastuzumab in Treating Patients With Stage IV Breas NCT00331552 | University of Washington | Phase 1 / Phase 2 |
| Completed | Ixabepilone and Liposomal Doxorubicin in Advanced Ovarian Cancer NCT00182767 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | A Phase II Study of AZD2171 in Breast Cancer Stage IV (10006202) NCT00244881 | National Cancer Institute (NCI) | Phase 2 |
| Completed | ONTAK® in Treating Patients With Advanced Breast Cancer That Did Not Respond to Previous Treatment NCT00425672 | University of Washington | Phase 1 / Phase 2 |
| Completed | Tipifarnib and Gemcitabine Hydrochloride in Treating Women With Metastatic Breast Cancer NCT00100750 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Terminated | Tanespimycin in Treating Women With Refractory Locally Advanced or Metastatic Breast Cancer NCT00096109 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Lapatinib/Carboplatin/Paclitaxel in Previously Treated Ovarian or Breast Cancer Patients NCT00316407 | Swedish Medical Center | Phase 1 / Phase 2 |
| Terminated | Suberoylanilide Hydroxamic Acid in Treating Patients With Progressive Stage IV Breast Cancer NCT00132002 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Sorafenib and Anastrozole in Treating Postmenopausal Women With Metastatic Breast Cancer NCT00217399 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Lapatinib and Tamoxifen in Treating Patients With Locally Advanced or Metastatic Breast Cancer That Did Not Re NCT00118157 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Trastuzumab, Ixabepilone, and Carboplatin in Treating Patients With HER2/Neu-Positive Metastatic Breast Cancer NCT00077376 | National Cancer Institute (NCI) | Phase 2 |
| Completed | FR901228 in Treating Patients With Metastatic Breast Cancer NCT00098397 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Lapatinib in Treating Brain Metastases in Patients With Stage IV Breast Cancer and Brain Metastases NCT00098605 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | 3-AP and Gemcitabine in Treating Patients With Refractory Metastatic Breast Cancer NCT00095888 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Sorafenib in Treating Patients With Metastatic Breast Cancer NCT00096434 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors NCT00089362 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Capecitabine and Tipifarnib in Treating Women With Taxane-Resistant Metastatic Breast Cancer NCT00077363 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Vaccine Therapy in Treating Patients Receiving Trastuzumab For HER2-Positive Stage IIIB-IV Breast Cancer NCT00343109 | University of Washington | Phase 2 |
| Completed | Tipifarnib and Fulvestrant in Hormone Receptor-Positive Metastatic Breast Cancer NCT00082810 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Trastuzumab and Ixabepilone in Treating Women With HER2-Positive Metastatic Breast Cancer NCT00079326 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Vaccine Therapy in Treating Patients With Metastatic Breast Cancer NCT00071942 | National Cancer Institute (NCI) | Phase 1 |
| Completed | GTI-2040 and Capecitabine in Treating Patients With Metastatic Breast Cancer NCT00068588 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Anastrozole and ZD1839 Compared With Fulvestrant and ZD1839 in Postmenopausal Women w/ Metastatic Breast Cance NCT00057941 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Cyclophosphamide or Denileukin Diftitox Followed By Expanding a Patient's Own T Cells in the Laboratory in Tre NCT00228358 | University of Washington | Phase 1 |
| Terminated | Oblimersen Plus Doxorubicin and Docetaxel in Treating Patients With Metastatic or Locally Advanced Breast Canc NCT00063934 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive Cancer NCT00060372 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Suramin and Paclitaxel in Treating Women With Stage IIIB-IV Breast Cancer NCT00054028 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Erlotinib Hydrochloride and Bevacizumab in Treating Patients With Stage IV Breast Cancer NCT00054132 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Imatinib Mesylate in Treating Patients With Metastatic Breast Cancer NCT00045188 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Bevacizumab and Docetaxel in Treating Women With Locally Advanced or Metastatic Breast Cancer NCT00055861 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Trastuzumab and Flavopiridol in Treating Patients With Metastatic Breast Cancer NCT00039455 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Trastuzumab and Gefitinib in Treating Patients With Metastatic Breast Cancer NCT00024154 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction NCT00030498 | National Cancer Institute (NCI) | Phase 1 |
| Completed | 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid NCT00031681 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Decitabine in Treating Patients With Advanced Solid Tumors NCT00030615 | National Cancer Institute (NCI) | Phase 1 |
| Completed | A Study of Gemcitabine, Epirubicin, and Paclitaxel Combination Chemotherapy Given Before Surgery to Patients W NCT00378313 | NSABP Foundation Inc | Phase 2 |
| Completed | Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer NCT00028496 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Vaccine Therapy With Sargramostim (GM-CSF) in Treating Patients With Her-2 Positive Stage III-IV Breast Cancer NCT00436254 | University of Washington | Phase 1 |
| Completed | PS-341 in Treating Women With Metastatic Breast Cancer NCT00025584 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Trastuzumab in Combination With Vinorelbine or Taxane-Based Chemotherapy in Patients With Metastatic Breast Ca NCT00146549 | Dana-Farber Cancer Institute | Phase 3 |
| Terminated | Combination Chemotherapy, Surgery, and Radiation Therapy With or Without Dexrazoxane and Trastuzumab in Treati NCT00016276 | National Cancer Institute (NCI) | Phase 3 |
| Completed | Bevacizumab Plus Vinorelbine in Treating Patients With Stage IV Breast Cancer NCT00017394 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Combination Chemotherapy With or Without Trastuzumab in Treating Women With Metastatic Breast Cancer NCT00004888 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Trastuzumab and Interleukin-2 in Treating Patients With Metastatic Breast Cancer NCT00006228 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Rebeccamycin Analogue in Treating Women With Stage IIIB or Stage IV Breast Cancer NCT00005817 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu NCT00004074 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Paclitaxel With or Without Trastuzumab in Treating Patients With or Without HER-2/Neu Breast Cancer That is In NCT00003440 | National Cancer Institute (NCI) | Phase 3 |
| Completed | Combination Chemotherapy and Peripheral Blood Stem Cell Transplant Followed By Aldesleukin and Sargramostim in NCT00003199 | Fred Hutchinson Cancer Center | Phase 2 |
| Terminated | Antineoplaston Therapy in Treating Women With Stage IV Breast Cancer NCT00003454 | Burzynski Research Institute | Phase 2 |
| Withdrawn | Methotrexate With or Without Antineoplaston Therapy in Treating Postmenopausal Women With Advanced Refractory NCT00003536 | Burzynski Research Institute | Phase 2 |
| Withdrawn | Antineoplaston Therapy in Treating Women With Advanced Breast Cancer NCT00003455 | Burzynski Research Institute | Phase 2 |
| Withdrawn | Trastuzumab With or Without Tamoxifen in Treating Women With Progressive Stage IV Breast Cancer NCT00053339 | Alliance for Clinical Trials in Oncology | Phase 3 |